Scarica l'app Stockscreener
0.6885
2.89%
-0.0205
Precedente Chiudi:
$0.709
Aprire:
$0.7097
Volume 24 ore:
30,886
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.37M
Reddito:
$14.64M
Utile/perdita netta:
$-13.74M
Rapporto P/E:
-0.0658
EPS:
-10.47
Flusso di cassa netto:
$-5.04M
1 W Prestazione:
-5.30%
1M Prestazione:
+10.85%
6M Prestazione:
-85.03%
1 anno Prestazione:
-93.72%
Intervallo 1D:
$0.68
$0.728
Intervallo di 1 settimana:
$0.676
$0.74
Portata 52W:
$0.3611
$11.45
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Nome
Novabay Pharmaceuticals Inc
Settore
Industria
Telefono
510-899-8800
Indirizzo
2000 Powell Street, Suite 1150, Emeryville, CA
Confronta NBY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NBY | 0.6823 | 3.37M | 14.64M | -13.74M | -5.04M | -10.47 |
| VRTX | 448.93 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.47 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.75 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.43 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-09-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Reiterato | Laidlaw | Buy |
| 2017-06-05 | Iniziato | ROTH Capital | Buy |
| 2017-03-27 | Iniziato | Laidlaw | Buy |
| 2017-02-06 | Iniziato | Rodman & Renshaw | Buy |
| 2016-03-07 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-14 | Reiterato | Maxim Group | Buy |
| 2015-04-30 | Ripresa | Maxim Group | Buy |
| 2013-03-06 | Iniziato | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | Iniziato | Dawson James | Speculative Buy |
Mostra tutto
Novabay Pharmaceuticals Inc Borsa (NBY) Ultime notizie
NovaBay calls for affirmative vote on asset sale and dissolution - Investing.com
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price - StockTitan
NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com
# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova Assets - Vision Monday
Novabay Pharmaceuticals Inc (NBY) Stock: A Year of Market Fluctuations - The InvestChronicle
Before You Invest, Make Sure You Check This Novabay Pharmaceuticals Inc (AMEX: NBY) Analysis - Stocks Register
Novabay Pharmaceuticals Inc (NBY)’s Market Momentum: Closing Strong at 0.70, Down -5.62 - The Dwinnex
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $2.83 million in funding from Pioneer Pharma Pte. Ltd. and other investors. - Marketscreener.com
A new trading data show Novabay Pharmaceuticals Inc (NBY) is showing positive returns. - SETE News
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - PR Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
NBY’s price-to-free cash flow ratio: What it means for investors - US Post News
NovaBay sells Avenova brand to PRN for $9.5 million - Investing.com
PRN Nutriceuticals agreed to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc.. - Marketscreener.com
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders - Business Wire
NovaBay sells Avenova brand to PRN for $9.5 million By Investing.com - Investing.com South Africa
NovaBay Pharma Announces Avenova Sale and Planned Dissolution - TipRanks
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - PR Newswire
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets - StockTitan
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.
Was there any good news for Novabay Pharmaceuticals Inc (NBY) stock in the last session? - US Post News
Novabay Pharmaceuticals Inc Inc. (NBY) Price Performance: The Role of Supply and Demand - The InvestChronicle
NovaBay Pharmaceuticals (NYSE:NBY) Announces Quarterly Earnings Results - Defense World
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2024 Earnings Call Transcript - Insider Monkey
Novabay Pharmaceuticals Inc (NBY)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
NovaBay Pharmaceuticals Reports Mixed Second Quarter 2024 Financial Results - Vision Monday
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare By Investing.com - Investing.com Canada
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare - Investing.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Crosses Above 50-Day Moving Average of $0.00 - Defense World
NovaBay To Hold 2017 Second Quarter Conference Call On August 10, 2017 - BioSpace
NBY Stock Earnings: NovaBay Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results - wallstreet:online
Ratio Analysis: Unpacking Novabay Pharmaceuticals Inc (NBY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
NBY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
NovaBay stock hits 52-week low at $0.47 amid steep annual decline - Investing.com
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering - Vision Monday
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 - StockTitan
Adversity is less terrifying than hope: Novabay Pharmaceuticals Inc (NBY) - SETE News
Novabay Pharmaceuticals Inc Azioni (NBY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):